Immune‐Related Adverse Events in Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors: Insights From a FAERS Disproportionality Analysis

ABSTRACT Introduction Immune checkpoint inhibitors (ICIs) are an important treatment option in bladder cancer, but clinical trials have demonstrated that they are associated with immune‐related adverse events (irAEs), such as rash, hypothyroidism, hyperthyroidism, and others. This study aimed to eva...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Pooja Gokhale, Lorenzo Villa Zapata
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Wiley 2026-04-01
Rangatū:	Cancer Medicine
Ngā marau:	bladder cancer disproportionality analysis FDA adverse event reporting system (FAERS) immune checkpoint inhibitors immune‐related adverse events
Urunga tuihono:	https://doi.org/10.1002/cam4.71777
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!